Development of the Tailored Rett Intervention and Assessment Longitudinal (TRIAL) database and the Rett Evaluation of Symptoms and Treatments (REST) Questionnaire.

about

Development of the Tailored Rett Intervention and Assessment Longitudinal (TRIAL) database and the Rett Evaluation of Symptoms and Treatments (REST) Questionnaire.

Item

http://www.wikidata.org/entity/Q38715062

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Development of the Tailored Re ...... eatments (REST) Questionnaire.

@en

type

Item

label

Development of the Tailored Re ...... eatments (REST) Questionnaire.

@en

prefLabel

Development of the Tailored Re ...... eatments (REST) Questionnaire.

@en

P1476

Development of the Tailored Re ...... eatments (REST) Questionnaire.

@en

P2093

Federico Fiori

http://www.w3.org/2001/XMLSchema#string

Jatinder Singh

http://www.w3.org/2001/XMLSchema#string

Kate Lievesley

http://www.w3.org/2001/XMLSchema#string

P2860

Rett syndrome: revised diagnostic criteria and nomenclature

Rett Syndrome: Crossing the Threshold to Clinical Translation

Illness Severity, Social and Cognitive Ability, and EEG Analysis of Ten Patients with Rett Syndrome Treated with Mecasermin (Recombinant Human IGF-1).

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

Reversal of neurological defects in a mouse model of Rett syndrome

Manipulations of MeCP2 in glutamatergic neurons highlight their contributions to Rett and other neurological disorders

Restoration of Mecp2 expression in GABAergic neurons is sufficient to rescue multiple disease features in a mouse model of Rett syndrome.

Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome.

P304

e015342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJOPEN-2016-015342

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paramala J Santosh

P577

2017-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28637735

http://www.w3.org/2001/XMLSchema#string

P932

5734452

http://www.w3.org/2001/XMLSchema#string